Detalhe da pesquisa
1.
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Lancet Oncol
; 24(1): 33-44, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460017
2.
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Lancet Oncol
; 24(9): 1029-1041, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37657462
3.
A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer.
Breast Cancer Res Treat
; 185(3): 807-815, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33090268
4.
A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer.
Breast Cancer Res Treat
; 185(2): 507-515, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33064230
5.
Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy.
Eur J Cancer
; 178: 180-190, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455412
6.
Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies.
Drug Saf
; 45(12): 1491-1499, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36310331
7.
First-line atezolizumab monotherapy in patients with advanced BRAFV600 wild-type melanoma.
Pigment Cell Melanoma Res
; 34(5): 973-977, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33476492
8.
A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple-negative breast cancer.
Cancer Med
; 9(20): 7548-7557, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32862501
9.
Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 25(2): e81-e86.e4, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38245456